-
Mashup Score: 1Analyzing determinants of premature trial discontinuation in leukemia clinical trials - 13 day(s) ago
Clinical trials are crucial for improving patient outcomes. Although a significant number of trials are discontinued prematurely, our understanding of factors influencing early termination is limit…
Source: www.tandfonline.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Analyzing determinants of premature trial discontinuation in leukemia clinical trials - 13 day(s) ago
Clinical trials are crucial for improving patient outcomes. Although a significant number of trials are discontinued prematurely, our understanding of factors influencing early termination is limit…
Source: www.tandfonline.comCategories: General Medicine News, Hem/OncsTweet-
Our newest paper co-led by our @YaleMed resident Lara Rotter & outstanding 🇯🇴graduate @Alhajahjeh_Abd (applying for #Match2025 so IM program directors pay close notice) Analyzing determinants of premature trial discontinuation in leukemia clinical trials https://t.co/nbORcdmn3S
-
-
Mashup Score: 17
Need help making sense of the rapidly changing diagnosis and treatment standards in higher-risk myelodysplastic syndrome (HR-MDS)?
Source: www.medscape.orgCategories: General Medicine News, Hem/OncsTweet-
Practical Pearls: Staying Up to Date on Higher-Risk Myelodysplastic Syndrome https://t.co/coVfHBMLZS via @MedscapeCME
-
-
Mashup Score: 75Targeted therapies for myelodysplastic Syndromes/Neoplasms (MDS): current landscape and future directions - 1 month(s) ago
Myelodysplastic syndromes/neoplasms (MDS) are a heterogeneous group of hematologic malignancies that are stratified into high-risk (HR-MDS) and low-risk (LR-MDS) categories. Until recently LR-MDS h…
Source: www.tandfonline.comCategories: General Medicine News, Hem/OncsTweet-
All you need to know about Targeted therapies for myelodysplastic syndromes (#MDSsm): current & future directions. Our recent review led by star resident @ABidikianMD & our team at @YaleCancer @YaleHematology @YaleMed @YaleMedicine @MarkDSiegel1 https://t.co/exg8dh0vTZ
-
-
Mashup Score: 75Targeted therapies for myelodysplastic Syndromes/Neoplasms (MDS): current landscape and future directions - 1 month(s) ago
Myelodysplastic syndromes/neoplasms (MDS) are a heterogeneous group of hematologic malignancies that are stratified into high-risk (HR-MDS) and low-risk (LR-MDS) categories. Until recently LR-MDS h…
Source: www.tandfonline.comCategories: General Medicine News, Hem/OncsTweet-
All you need to know about Targeted therapies for myelodysplastic syndromes (#MDSsm): current & future directions. Our recent review led by star resident @ABidikianMD & our team at @YaleCancer @YaleHematology @YaleMed @YaleMedicine @MarkDSiegel1 https://t.co/exg8dh0vTZ
-
-
Mashup Score: 28Cancer Care in Resource-Limited Countries: Jordan as an Example | JCO Global Oncology - 1 month(s) ago
Jordan, a lower- to middle-income country, is relatively small, but with rapidly growing population and a challenged economy. Cancer is a growing health care problem and currently ranked second, after cardiovascular diseases, as a cause of death. Jordan’s …
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Outstanding review on how to deliver top notch cancer care despite limited resources using @KHCFKHCC as a model under leadership of HRH Princess @GhidaTalal is published in JCO Global Oncology Cancer Care in Resource-Limited Countries: Jordan as an Example https://t.co/211WZe0QzO
-
-
Mashup Score: 4Chronic Malignancies Working Party Educational Meeting 2024 - 1 month(s) ago
The Chronic Malignancies Working Party (CMWP) of EBMT is delighted to announce our Scientific Business Meeting and Educational Meeting which will be held on 22 and 23 November 2024 in Warsaw, Poland. The specific focus of this meeting will be on optimisation of allogeneic HCT for MDS, MPN and MDS/MPN overlap syndromes. The Scientific Business Meeting gives an opportunity to hear about the progress of our study portfolio, suggest new studies and contribute to the work of the CMWP. The Educational Meeting
Source: www.ebmt.orgCategories: General Medicine News, Hem/OncsTweet-
RT @KatjaSockel: 👇Don’t miss this fantastic meeting on alloHCT in #MDS and #MPN! See you in Warsaw 22-23 November! https://t.co/6igO8nAufi…
-
-
Mashup Score: 12Advances in MDS Classification and Molecular Understanding - 2 month(s) ago
After a brief introduction, medical experts discuss advances in MDS classification and molecular understanding.
Source: www.ajmc.comCategories: General Medicine News, Hem/OncsTweet-
Advances in #MDSsm Classification and Molecular Understanding https://t.co/iW2jrymdEC via @AJMC
-
-
Mashup Score: 12ASCERTAIN Data: Oral Decitabine-Cedazuridine Outcomes in MDS - 2 month(s) ago
Medical experts discuss the data gathered from the ASCERTAIN trial.
Source: www.ajmc.comCategories: General Medicine News, Hem/OncsTweet-
ASCERTAIN Data: Oral Decitabine-Cedazuridine Outcomes in #MDSsm https://t.co/wZbeGclrXz via @AJMC
-
-
Mashup Score: 34
Background: Hypomethylating agents (HMAs) are guideline-recommended treatment for higher-risk myelodysplastic syndromes/neoplasms (MDS). However, a prior survey…
Source: journals.sagepub.comCategories: General Medicine News, Hem/OncsTweet-
Our newest paper is a 150 #MDSsm patient Survey suggesting very little/no impact on regular daily activities & improved QOL with oral DEC-C relative to IV/SC HMAs, highlighting potential for oral HMA to reduce treatment burden compared to parenteral HMA. https://t.co/U2EUXGbQjH
-
Our newest paper co-led by our @YaleMed resident Lara Rotter & outstanding 🇯🇴graduate @Alhajahjeh_Abd (applying for #Match2025 so IM program directors pay close notice) Analyzing determinants of premature trial discontinuation in leukemia clinical trials https://t.co/nbORcdmn3S